- Pfizer (NYSE:PFE) acquires GlaxoSmithKline's (NYSE:GSK) quadrivalent (A,C,Y and W-135) meningitis vaccines, Nimenrix and Mencevax, for $130M (€115M).
- Nimenrix is a single-dose meningococcal conjugated vaccine designed to protect against Neisseria meningitidis, an uncommon but highly contagious and potentially life-threatening disease. It is approved for sale in 61 countries outside of the U.S.
- Mencevax, currently approved for sale in 79 countries outside the U.S., is a single-dose meningococcal unconjugated polysaccharide vaccine used to control outbreaks of meningococcal infection and for travelers to countries where the disease is endemic or highly epidemic.
- Pfizer does not expect the deal to have a significant impact on its 2015 financials. The transaction should close in H2.